Sarlósejtes vérszegénység: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• G6PD 0
• NLRP3 0
• APOL1 0
• CD19 3
• BTK 0
• FGFR 0
• NRF2 0
• SGLT2 1
• CFTR 1
• CXCR4 0
• DMD 1
• GLP-1 0
• HDAC 1
• HMGB1 0
• HTT 1
• JAK 0
• NF1 1
• SMN1 1

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies (TARGET-SCD)

  Universite Paris Cite· Paris, Franciaország· EU contribution 2 449 320 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Deciphering Inflammatory and Placental Mechanisms of Pre-eclampsia in Sickle Cell Disease (PRECISE)

  Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation· Paris, Franciaország· EU contribution 242 261 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  A metabolic-based defense strategy against malaria (KILLBILL)

  Fundacao Gimm - Gulbenkian Institute for Molecular Medicine· Lisboa, Portugália· EU contribution 2 500 000 EUR· until 2031. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  CONSORTIUM FOR DEVELOPING REGULATORY CAPACITY FOR CLINICAL TRIALS USING GENE THERAPY PRODUCTS AND STRENGTHENING PHARMACOVIGILANCE IN THE CONDUCT OF CLINICAL TRIALS IN EAST AFRICA (CAPACITY 2023)

  Universidade de Coimbra· Coimbra, Portugália· EU contribution 999 315 EUR· until 2027. márc.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synthetic generation of hematological data over federated computing frameworks (SYNTHEMA)

  Universidad Politecnica de Madrid· Madrid, Spanyolország· EU contribution 6 514 560 EUR· until 2026. nov.· 10 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 8 running projects, newest first. Listed amounts together: 25,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 1
• CRISPR-Cas Systems 15
• Gene Expression Profiling 7
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 2
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 2
• Magnetic Resonance Imaging 21
• Machine Learning 5
• Deep Learning 3
• Cohort Studies 19
• Genome-Wide Association Study 5

• An AI-enabled tool for quantifying overlapping red blood cell sickling dynamics in microfluidic assays.

  Lab Chip, 2026. jún.

• Sickle cell disease detection in low-resource conditions using transfer-learning and contrastive-learning coupled with XAI.

  Sci Rep, 2026. jan.

• A multidimensional transformer-CNN network trained with incomplete ultrasonic radiofrequency data of blood for red blood cell aggregation classification.

  Phys Eng Sci Med, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.